Savient Shifts Focus To Puricase Submission For Refractory Gout
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm restructures its commercial operations and terminates 19-rep sales force detailing its anabolic agent Oxandrin.
You may also be interested in...
Watson Launches Authorized Oxandrin Generic
Launch follows denial of Savient’s motion for preliminary injunction to prevent Sandoz and Upsher-Smith from launching generic oral anabolic agent.
TAP To Discuss Gout Treatment With FDA Following Second “Approvable” Letter
Febuxostat would be the first new treatment for chronic gout in more than 40 years.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.